- Stocks
- Pharma & Healthcare
- Transchem
Transchem share price
NSE: TRANSCHEMPharma & HealthcareShell Companies
Transchem at a glance
With a market capitalisation of ₹391 Cr, it ranks 1913th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Shell Companies.
Its return on equity was 5.1% in FY26. Promoters held 56.45% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹391 CrRank 1913 on NSE
- Price to book
- 2.38×FY26
- EPS (TTM)
- ₹3.51to Q4 FY26
- ROE
- 5.1%FY26
- ROCE
- 6.7%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 0.0%FY26
- Book value / share
- ₹68.28FY26
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Transchem quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | ₹0 Cr | ₹2 Cr | — | — | — | — |
| Revenue YoY | — | — | — | +490.2% | — | — | — | — |
| Net profit | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr |
| Net profit YoY | +95.3% | +48.5% | +21.9% | −41.6% | −40.4% | −52.8% | −61.9% | +186.3% |
| Net margin | — | — | 661.9% | 30.2% | — | — | — | — |
| EPS | ₹1.36 | ₹1.18 | ₹1.13 | ₹0.60 | ₹0.81 | ₹0.56 | ₹0.43 | ₹1.71 |
Transchem financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹22 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹0 Cr |
| Operating profit | ₹25 Cr | ₹4 Cr | ₹3 Cr | ₹6 Cr | ₹7 Cr | ₹6 Cr |
| Net profit | ₹24 Cr | ₹3 Cr | ₹1 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr |
| EPS (₹) | ₹19.73 | ₹2.34 | ₹1.01 | ₹3.43 | ₹4.27 | ₹3.51 |
| Cash from operations | −₹28 Cr | ₹22 Cr | ₹1 Cr | −₹39 Cr | ₹36 Cr | −₹2 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹63 Cr | ₹66 Cr | ₹66 Cr | ₹76 Cr | ₹79 Cr | ₹84 Cr |
Transchem shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 56.45% | 56.45% | 56.45% | 56.45% | 56.45% | 56.45% |
| Foreign institutions | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% |
| Domestic institutions | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Non-institutions | 43.52% | 43.52% | 43.52% | 43.52% | 43.52% | 43.52% |
Transchem vs peers
The listed Pharma & Healthcare companies nearest to Transchem by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ALBERTDAVDAlbert David | ₹795.00 | −3.90% | −0.6% | ₹454 Cr | — | — |
| ASARFIAsarfi Hospital | — | — | — | ₹446 Cr | — | — |
| JENBURPHJenburkt Pharma | ₹905.20 | −1.63% | — | ₹399 Cr | 11.5 | — |
| TRANSCHEMTranschem | — | — | — | ₹391 Cr | — | — |
| APPLAptus Pharma | — | — | — | ₹377 Cr | — | — |
| MEDICAMEQMedicamen Biotech | ₹273.35 | −4.09% | −11.6% | ₹371 Cr | 37.9 | — |
| ASTALLTDAstal Lab | — | — | — | ₹358 Cr | — | — |
Ask anything about Transchem
Pivot answers on the live chart with evidence you can check, and tests strategies against TRANSCHEM's own history. Try: “Why has TRANSCHEM moved over the last three months?” · “Backtest a 50-day moving-average crossover on TRANSCHEM over five years” · “Compare TRANSCHEM with ALBERTDAVD on margins and valuation”
Frequently asked questions about Transchem
What is the market cap of Transchem?
Transchem's market capitalisation is ₹391 Cr (₹391 Cr) at the 19 Oct 2026 close, ranking 1913th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Transchem?
Return on equity was 5.1% in FY26 and return on capital employed was 6.7% in FY26 (standalone figures).
Is Transchem a debt-free company?
Transchem is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What is the shareholding pattern of Transchem?
As of 30 Jun 2026: promoters 56.45%, foreign institutions 0.03%, domestic institutions 0.01%, non-institutions 43.52%.
Who are Transchem's competitors?
The listed Pharma & Healthcare companies closest to Transchem by market cap are Albert David, Asarfi Hospital, Jenburkt Pharma, Aptus Pharma, Medicamen Biotech and Astal Lab.
Is Transchem a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Transchem's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TRANSCHEM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with T · all NSE stocks · this page as text